Boston Scientific is poised to release its third-quarter results later this month, and analysts project a double-digit ...

The company has now treated 500,000 patients with its pulsed field ablation system, in a competitive category poised for ...

Boston Scientific Corp. has announced it has received FDA approval and market launch of its Epic vascular self-expanding stent system, according to a news release. Boston Scientific said the Epic ...

Across the recent three months, 12 analysts have shared their insights on Boston Scientific (NYSE: BSX), expressing a variety ...

To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income ...

The Food and Drug Administration (FDA) said on Wednesday it is monitoring a potential safety issue involving Boston Scientific Corporation’s (NYSE:BSX) ENDOTAK RELIANCE defibrillation leads, following ...

Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market - GAITHERSBURG, Md., ...

Fintel reports that on October 2, 2025, Barclays maintained coverage of Boston Scientific (NYSE:BSX) with a Overweight ...